{"id":"NCT03237325","sponsor":"Soligenix","briefTitle":"DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer","officialTitle":"A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-04","primaryCompletion":"2020-06-24","completion":"2021-06-24","firstPosted":"2017-08-02","resultsPosted":"2022-08-29","lastUpdate":"2022-11-08"},"enrollment":266,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Squamous Cell Carcinoma of the Oral Cavity and Oropharynx","Oral Mucositis"],"interventions":[{"type":"DRUG","name":"SGX942","otherNames":["Dusquetide"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SGX942","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis in patients receiving chemoradiation treatment for the treatment of head and neck cancer","primaryOutcome":{"measure":"Duration of Severe Oral Mucositis (SOM)","timeFrame":"approx. 13 weeks","effectByArm":[{"arm":"SGX942","deltaMin":12.5,"sd":null},{"arm":"Placebo","deltaMin":20,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1798"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":10},"locations":{"siteCount":53,"countries":["United States","Belgium","France","Spain","United Kingdom"]},"refs":{"pmids":["27015977","27746305","28649557"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":74,"n":127},"commonTop":["Nausea","Constipation","Dry mouth","Fatigue","Dysgeusia"]}}